# Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma

> **NCT01545427** · PHASE2 · TERMINATED · sponsor: **London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's** · enrollment: 10 (actual)

## Conditions studied

- Scleroderma

## Interventions

- **DRUG:** Imatinib mesylate
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01545427
- **Lead sponsor:** London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-04
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Frequent adverse events occurred early in treatment with poor tolerability.
- **Last updated:** 2012-03-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01545427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01545427, "Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01545427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*